Caroline C. Wasén currently works at the Ann Romney Center for Neurological Disease, Brigham and Womens Hospital, Harvard Medical School, in collaboration with the Department of Rheumatology and Inflammation Research (DRIR), University of Gothenburg. She conducts research on the microbiome in Alzheimer's disease and the immune system of the CNS in rheumatoid arthritis.
David M. Holtzman is a world-renowned physician-scientist and is currently a Professor of Neurology, scientific director of the Hope Center for Neurological Disorders, and Director of the Knight ADRC at Washington University in St. Louis. He received his BS and MD degrees from Northwestern University, followed by a Neurology residency and postdoctoral training at UCSF. Over the last 30 years, His laboratory has focused on studying the molecular mechanisms underlying neurodegeneration and Alzheimer's disease, particularly the neurobiology of ApoE and its receptors, ApoE and TREM2 effects on the innate immune system, and how ApoE, Aß-binding molecules, and other factors such as neuronal activity and sleep influence Aß and tau metabolism and Alzheimer's disease progression. He has received multiple honors, and several of his accomplishments include being a recipient of the Potamkin Prize and MetLife award for research on Alzheimer's disease, the Rainwater Prize for outstanding innovation in neurodegenerative disease research, election to the National Academy of Medicine, election to the National Academy of Inventors, being appointed to the National Advisory Council of the NINDS and NIA, the Chancellor's Award for innovation and entrepreneurship and the Carl and Gerty Cori award from Washington University, elected Fellow of the AAAS, and being a past president of the American Neurological Association.
Takaomi C. Saido currently works as the Team Leader at the Laboratory of Proteolytic Neuroscience, RIKEN Center for Brain Science, Saitama, Japan. He received his Ph.D. in Pharmaceutical Science from the University of Tokyo in 1988. His primary scientific interests are in Alzheimer's disease, Biochemistry, Amyloid precursor protein, Molecular biology, and Calpain. His studies deal with areas such as Endocrinology, Neurodegeneration, Neuroscience, and Amyloid as well as Alzheimer's disease. His Amyloid research is multidisciplinary, incorporating elements of P3 peptide, Amyloid beta, Neprilysin, and Amyloidosis.
Laura M. Cox is an Assistant Professor in the Department of Neurology at the Ann Romney Center for Neurologic Diseases at Harvard Medical School and BWH. Her lab is currently investigating the role of the microbiome in neurologic diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis. She was originally trained as a clinical microbiologist, identifying infectious agents. She then obtained her PhD in the lab of Dr. Martin Blaser, where she found that early-life antibiotics lead to lasting metabolic consequences. To gain experience with models of neurologic disease, she then pursued postdoctoral training in the lab of Dr. Howard Weiner. She established her lab in the fall of 2021 and, through work supported by the CureAlz Foundation, has begun to identify age-related changes in the gut microbiota that may affect AD by modulating peripheral and central immunity.
